Hamilton Thorne Engages Bristol Capital to Provide Investor Relations and Communications Services

BEVERLY, Mass. and TORONTO, March 29, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading worldwide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, announced today that it has entered into a consulting agreement with Bristol Capital ("Bristol"), a leading investor relations and capital markets advisory firm servicing Canadian and US microcap and small cap companies across international markets to provide investor relations and communication services.

David Wolf, President and Chief Executive Officer stated, “Over the past few years we have substantially broadened our investor base from a small number of enthusiastic microcap investors to include significant Canadian, as well as some US and European, institutional ownership. We are now looking to support our existing investors and expand our institutional investor base across the US and Europe.”

Bristol has been retained for an initial term commencing on April 1, 2018, with automatic extension on a month to month basis, subject to early termination under certain circumstances. Bristol will be paid a monthly fee of between CDN$7,000 and CDN$9,000 depending on the level of services provided by Bristol to the Company in such month.

About Hamilton Thorne Ltd. (https://www.hamiltonthorne.com)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]

Glen Akselrod
Bristol Institutional Relations
905-326-1888
[email protected]